• Press Release: EpiVax Accelerates COVID-19 Vaccine Development with UGA’s Center for Vaccines and Immunology

    Posted on March 4, 2020 by Danielle Medeiros
    PROVIDENCE, R.I., Mar. 4, 2020 – EpiVax Inc., a Rhode Island company, announces a collaboration to develop a novel coronavirus SARS-CoV-2 (COVID-19) vaccine with University of Georgia (UGA, Athens GA) vaccine expert Ted Ross (Director, Center for Vaccines and Immunology (CVI)).  The COVID-19 virus emerged in January 2020, impacting over 94,000 individuals, in China and ...
    Read more
  • EpiVax devises ‘recipe’ for coronavirus vaccine – Providence Business News interview

    Posted on February 21, 2020 by Danielle Medeiros
    By Elizabeth Graham -February 21, 2020 2:35 am Find the full story here. Staying current on the frantic pace of the coronavirus outbreak means following reports by major news outlets for most people, but analysts at EpiVax Inc. are more interested in websites that share genetic sequences of the novel virus. Chinese health officials published the sequence in ...
    Read more
  • EpiVax worked for 21 years to be able to make a vaccine in 24 hours!

    Posted on February 10, 2020 by Danielle Medeiros
    EpiVax worked for 21 years to be able to make a vaccine in 24 hours!
    Read more
  • Press Release: EpiVax Announces Record Year for Growth in 2019 and Sets New Milestones for 2020

    Posted on December 27, 2019 by Sarah Moniz
    Providence, R.I., December 23, 2019 – EpiVax (“EpiVax, Inc.”) continues its record-breaking performance and growth in personnel in 2019 while identifying new milestones to aspire to in 2020. The Business Development team closed 15% more contracts over 2018 and acquired two new clients for ISPRI, the in silico immunogenicity screening and protein re-engineering interface, bringing the ...
    Read more
  • Press Release: On Eve of New Decade, EpiVax Re-Pledges Commitment to Improving Health Everywhere

    Posted on December 20, 2019 by Sarah Moniz
    Providence, R.I., December 17, 2019 EpiVax, Inc. (“EpiVax”), the home of “fearless science”, announces it will renew their company-wide commitment to “improving human health everywhere” in the new decade (2020). EpiVax has a greater than 20-year tradition of corporate giving to worthy charities, especially those that improve human (or animal) health. Each year a significant portion ...
    Read more
  • Press release: EpiVax’s Novel Tregitope technology offers promising outcomes in the Treatment of Type 1 Diabetes

    Posted on November 6, 2019 by Danielle Medeiros
    Providence, November 6th 2019 EpiVax announces Publication of Antigen-Specific Tolerance Induction by Tregitope in Nature Scientific Reports EpiVax, Inc (“EpiVax”), a pioneer in immunoinformatics innovation, announces the publication of “Therapeutic administration of Tregitope-Human Albumin Fusion with Insulin Peptides to promote Antigen-Specific Adaptive Tolerance Induction” in Scientific Reports, 06 Nov 2019, a Nature publication .  This research highlights ...
    Read more
  • Press Release: Chugai Renews License to EpiVax’s ISPRI In Silico Toolkit for Immunogenicity Assessment

    Posted on October 23, 2019 by Danielle Medeiros
    Announced today, Chugai Pharmaceutical Co., Ltd. (“Chugai”), a member of the Roche Group, will extend the company’s licensed access to the Immunogenicity Screening and Protein Reengineering Interface (ISPRI) toolkit developed by EpiVax, Inc. (“EpiVax”). Chugai, one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products, integrated the advanced ISPRI toolkit into their preclinical assessment pipeline after an extended head-to-head comparison with other in ...
    Read more
  • EpiVax, Turning 21, Celebrates Birthday by “Improving Human Health Everywhere”

    Posted on May 28, 2019 by Kathleen Gonzalez
    Providence, R.I., May 28, 2019 – EpiVax, Inc. is celebrating the company’s 21st birthday in Providence by renewing its commitment to improving human health everywhere and highlighting the work of two not-for-profit organizations that have been partners with EpiVax for nearly all of those 21 years. Clínica Esperanza/Hope Clinic (CEHC) is located near EpiVax’s headquarters in ...
    Read more
  • EpiVax Oncology To Present Latest Research On The Importance Of Identifying And Removing, Using Machine-Learning Based Advanced Computational Tools, Inhibitory Neoantigens From Therapeutic Cancer Vaccines, At AACR Annual Meeting 2019

    Posted on March 28, 2019 by Kathleen Gonzalez
    THIS ORIGINAL ARTICLE WAS PUBLISHED IN PR NEWSWIRE. LINK TO THE ORIGINAL ARTICLE CAN BE FOUND HERE. NEW YORK, March 25, 2019 /PRNewswire/ — EpiVax Oncology, Inc., a precision cancer immunotherapy company, today announced that its abstract has been selected for an oral presentation, at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2019, taking place on March ...
    Read more
  • EpiVax Gives Back in 2018, Looks Forward to 2019!

    Posted on December 29, 2018 by Annie De Groot
    Making Epi-Resolutions for 2019: In 2019, EpiVax will strive to help improve human-to-human interactions, while supporting the right of every human to speak freely, to be healthy, to build diverse communities and to wage peace. We will also promote humane practices towards animals and work to protect and honor the Earth, our home. And, of course, ...
    Read more
  • Leslie J. De Groot MD, 1928-2018

    Posted on October 23, 2018 by Annie De Groot
    Leslie J. DeGroot MD (“Les”) was born on a dairy farm in Fort Edward NY in 1928, dedicated his life to thyroid disease research and endocrinology and died soon after his 90th birthday, on October 23, 2018 in Nonquitt, Massachusetts, surrounded by his many loving grandchildren, children and his wife.
    Read more
  • Breaking News: FDA awards $1 million to EpiVax, CUBRC, to assess generic peptide drugs

    Posted on October 5, 2018 by Kathleen Gonzalez
    This original article was published on October 2nd, 2018 in ConvergenceRI. PROVIDENCE, RI – The U.S. Food and Drug Administration announced on Tuesday, Oct. 2, that the federal agency has awarded EpiVax and CUBRC a $1 million contract over two years to establish best practices and procedures to evaluate generic peptide drugs for immunogenic potential and related ...
    Read more
  • PANDA: The Newest Product at EpiVax

    Posted on October 2, 2018 by Kathleen Gonzalez
    EpiVax has been awarded a $1 million contract from the Food and Drug Administration (FDA) to demonstrate and validate the best practices and procedures for assessing generic peptide drugs and related impurities for immunogenic potential.
    Read more
  • EpiVax Oncology Completes a $1.2M Bridge Financing

    Posted on June 13, 2018 by Sarah Moniz
    NEW YORK CITY AND PROVIDENCE, RI., June 12, 2018 (BUSINESS WIRE) — EpiVax Oncology, Inc., a precision cancer immunotherapy company, today announced the closing of a $1.2M Bridge Financing. The investors include NextWaveBio, Morningside Venture Investments, Accelerate NY Seed Fund and Horatio Ventures NYC. EpiVax Oncology, Inc. (EO) is developing precision cancer immunotherapies based on Neo-Epitopes ...
    Read more
  • EpiVax Opens New Headquarters and Celebrates 20 Years of Fearless Science

    Posted on June 11, 2018 by Sarah Moniz
    PROVIDENCE, R.I., June 11, 2018 — EpiVax announces their move to a new headquarters at 188 Valley Street, in the “Rising Sun” complex, a former wool mill in the Olneyville section of Providence, Rhode Island. The privately held bioinformatics company is also celebrating its 20th anniversary. The mission of EpiVax is to “improve human health everywhere” through ...
    Read more

Join our newsletter

We strive to provide our clients, collaborators and everyday immunology enthusiasts with valuable content.  Written by our CEO/CSO Dr. Anne Dr Groot, you can expect up to date vaccine development efforts, upcoming events and so much more from our offices here in Providence, RI.

Click Here